GS-9137. Anti-HIV agent HIV integrase inhibitor

Drugs of the Future

Volumn 31, Issue 4, 2006, Pages 310-313

  Sorbera, L A ^a   Serradell, N ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DNA; GS 9137; INTEGRASE; INTEGRASE INHIBITOR; JTK 303; L 870812; MK 518; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITONAVIR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS STRAIN;

EID: 33745218564     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.04.982081     Document Type: Review

References (19)

1. Satoh, M., Kawakami, H., Itoh, Y. et al. (Japan Tobacco Inc.). 4-Oxoquinoline compounds and utilization thereof as HIV integrase inhibitors. EP 1564210, JP 2005002092, US 2005239819, WO 2004046115.
2. Satoh, M., Matsuda, T., Okuda, S. et al. (Japan Tobacco Inc.). Novel 4-oxoquinoline compound and use thereof as HIV integrase inhibitor. WO 2005113509.
3. Satoh, M., Motomura, T., Matsuda, T. et al. (Japan Tobacco Inc.). Stable crystal of 4-oxoquinoline compound. JP 2006001927, WO 2005113508.
4. Sato, M., Motomura, T., Aramaki, H. et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006, 49(5): 1506-8.
5. Prous Science Drug R&D Backgrounders: HIV and AIDS (online publication). Updated March 21, 2006.
6. Pommier, Y., Johnson, A.A., Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005, 4(3): 236-48.
7. Craigie, R. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem 2001, 276: 23213-5.
8. Richman, D.D. HIV chemotherapy. Nature 2001, 410: 995-1001.
9. Weiss, R.A. HIV and AIDS: Looking ahead. Nat Med 2003, 9: 887-91.
10. Johnson, A.A., Marchand, C., Pommier, Y. HIV-1 integrase inhibitors: A decade of research and two drugs in clinical trial. Curr Top Med Chem 2004, 4: 1059-77.
11. Barreca, M.L., Ferro, S., Rao, A. et al. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J Med Chem 2005, 48: 7084-8.
12. Hazuda, D.J., Young, S.D., Guare, J.P. et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004, 305: 528-32.
13. Hazuda, D.J., Felock, P., Witmer, M. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287: 646-50.
14. Sechi, M., Derudas, M., Dallacchio, R. et al. Design and synthesis of novel indole beta-diketo acid derivatives as HIV-integrase inhibitors. J Med Chem 2004, 47: 5298-310.
15. Matsuzaki, Y., Watanabe, W., Yamataka, K. et al. JTK-303/GS 9137, novel small-molecule inhibitor of HIV-1 integrase: Anti-HIV activity profile and pharmacokinetics in animals. 13th Conf Retroviruses Opportunistic Infect (Feb 5-9, Denver) 2006, Abst 508.
16. Kawaguchi, I., Ishikawa, T., Ishibashi, M., Irie, S., Kakee, A. Safety and pharmacokinetics of single oral dose of JTK-303/GS 9137, a novel HIV integrase inhibitor, in healthy volunteers. 13th Conf Retroviruses Opportunistic Infect (Feb 5-9, Denver) 2006, Abst 580.
17. DeJesus, E., Berger, D., Markowitz, M. et al. The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naïve and experienced patients. 13th Conf Retroviruses Opportunistic Infect (Feb 5-9, Denver) 2006, Abst 160LB.
18. Gilead announces results from phase I/II study of investigational HIV integrase inhibitor GS 9137. Gilead Sciences Press Release 2006, February 9.
19. Ritonavir-boosted GS-9137 vs. ritonavir-boosted protease inhibitor(s) in combination with background ART (NCT00298350). ClinicalTrials.gov Web Site 2006, February 28.